Register for free to
view the full innovation profile.
The drug is safe as it is used at a lower light irradiation and can be used with magnetic resonance imaging (MRI) for early-stage disease diagnosis..
About
The drug of the present invention is porphyrin-lanthanide complexes with specific functional groups which are conjugated with carefully chosen peptides so as to increase cancer cells specificity. In-house studies showed that the drug is able to significantly kill cancer cells without attacking normal cells and can give responsive emission for diagnostics.
Key Benefits
The drug is safe as it is used at a lower light irradiation (i.e. 10 J/cm2 vs standard dose of 50 J/cm2) and can be used with magnetic resonance imaging (MRI) for early-stage disease diagnosis. It is less invasive when comparing to positron emission tomography (PET) and X-ray computer tomography. With the MRI, the drug provides high-resolution images for accurate diagnosis of cancer. Besides, it will only attack cancer cells instead of normal cells. Therefore, it will not induce adverse effects in patients during and after the treatment.
Applications
The drug can be used for early-stage cancer diagnosis and killing cancer cells in-situ.